Novartis Investigative Site

Goudi- Athens 115 27

0 studies enrolling now · 2 studies all time

What they study most

Retinopathy of Prematurity, Systemic Juvenile Idiopathic Arthritis

Studies at this site

• An Open-label Extension Study of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis and Active Systemic Manifestations Manifestations and Response Characterization Study in Canakinumab Treatment-naïve Patients With Active SJIA With and Without Fever. — Completed
• RAINBOW Study: RAnibizumab Compared With Laser Therapy for the Treatment of INfants BOrn Prematurely With Retinopathy of Prematurity — Completed